US EditionEntrada receives authorization in the United Kingdom to start a Phase 1/2 Duchenne trial skipping exon 45
Summary by CureDuchenne
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Entrada receives authorization in the United Kingdom to start a Phase 1/2 Duchenne trial skipping exon 45
Entrada trial skipping exon 45 CureDuchenne provided early funding to Entrada Therapeutics, who has announced that they received authorization in the United Kingdom (UK) to initiate a Phase 1/2 multiple ascending dose clinical trial in individuals with Duchenne amenable to skipping exon 45. They plan to start that trial in Q3 2025. This is the second clinical exon-skipping program for Entrada, who has authorization for exon 44 skipping trials …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
